Keyphrases
1-year Follow-up
9%
Antidepressants
9%
Antipsychotics
27%
Clinical Outcomes
9%
Clozapine
9%
Database Linkage
9%
Efficacy-effectiveness Gap
9%
Everyday Clinical Practice
9%
Everyday Practices
100%
Exclusion Criteria
9%
Finland
9%
Hazard Ratio
27%
High Risk
9%
History of Suicide
9%
Hospitalization Risk
36%
Ineligibility
18%
Maintenance Treatment
18%
Mood Stabilizers
9%
National Patient Registry
9%
Outpatient Care
9%
Patients with Schizophrenia
9%
Psychosis
45%
Randomized Clinical Trial
100%
Real-world Population
27%
Relapse Prevention
9%
Schizophrenia
100%
Schizophrenia Spectrum Disorders
72%
Second-generation Antipsychotics
9%
Somatic Comorbidity
9%
Suicide Attempt
9%
Sweden
9%
Tardive Dyskinesia
9%
Treatment Discontinuation
9%
Treatment Resistance
9%
Unselected Patients
9%
Medicine and Dentistry
Antidepressant
9%
Antipsychotic
9%
Clozapine
9%
Comorbidity
9%
Diagnosis of Schizophrenia
9%
Exclusion Criterion
9%
Gene Linkage
9%
Hazard Ratio
27%
Maintenance Therapy
18%
Mood Stabilizer
9%
Outpatient Care
9%
Patient Registry
9%
Randomized Clinical Trials
100%
Relapse Prevention
9%
Schizophrenia Spectrum Disorder
72%
Somatics
9%
Suicide Attempt
9%
Tardive Dyskinesia
9%
Pharmacology, Toxicology and Pharmaceutical Science
Antidepressant
9%
Antipsychotic
9%
Clozapine
9%
Comorbidity
9%
Mood Stabilizer
9%
Patient Registry
9%
Randomized Clinical Trial
100%
Schizophrenia Spectrum Disorder
72%
Suicide Attempt
9%
Tardive Dyskinesia
9%
Psychology
Comorbidity
11%
Hazard Ratio
33%
Mood
11%
Relapse Prevention
11%
Schizophrenia
100%
Tardive Dyskinesia
11%
Immunology and Microbiology